R. Fleming

PTPN2 Deletion Enhances CAR-T Effector Function and CNS Trafficking in a Non-Human Primate Model.

B-cell targeting CAR-T cells (CAR-T) therapies achieve high remission rates, yet durable responses occur in fewer than 40% of patients. Deletion of negative T-cell regulators such as PTPN2, a key inhibitor of TCR and cytokine signaling, represents a promising strategy to enhance CAR-T efficacy. While transfer of PTPN2-...